Prc was Sinovac Biotech’s largest region in fiscal 2025, bringing in $261.18M of $386.01M (68%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outside Mainland China | $398.74M | — | — | — | ||||||||||||
| Prc | $1.07B | $402.96M | $297.00M | $261.18M | ||||||||||||
| Mainland China | — | — | — | — | ||||||||||||
| Cn | — | — | — | — | ||||||||||||
| Outside Chinese Mainland | — | $67.21M | $64.37M | $124.83M | ||||||||||||
| Foreign Countries | — | — | — | — | ||||||||||||
| Segment Geographical Groups Of Countries Group One | — | — | — | — | ||||||||||||
| Total | $1.47B | $470.17M | $361.37M | $386.01M |
Sinovac Biotech brought in $386.01M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 6.8% from $361.37M in fiscal 2024. Prc was the largest at $261.18M (67.7%), ahead of Outside Chinese Mainland at $124.83M (32.3%).
Compared with fiscal 2024, Outside Chinese Mainland grew 93.9% to $124.83M, while Prc fell 12.1% to $261.18M.
Sinovac Biotech began breaking out Outside Chinese Mainland in fiscal 2023, when it brought in $67.21M. Sinovac Biotech stopped reporting Outside Mainland China as a separate region after fiscal 2022, when it brought in $398.74M.
Chinese Mainland Private Market was Sinovac Biotech’s largest revenue line in fiscal 2025, bringing in $236.19M of $386.01M (61%).
| Contract with Customer, Sales Channel | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Epi | $695.84M | — | — | — | ||||
| Export | $398.74M | $67.21M | $64.37M | $124.83M | ||||
| Private Pay | $378.86M | — | — | — | ||||
| Chinese Mainland Private Market | — | $356.48M | $246.64M | $236.19M | ||||
| Chinese Mainland Public Market | — | $46.48M | $50.36M | $25.00M | ||||
| Total | $1.47B | $470.17M | $361.37M | $386.01M |
Sinovac Biotech brought in $386.01M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 6.8% from $361.37M in fiscal 2024. Chinese Mainland Private Market was the largest at $236.19M (61.2%), ahead of Export at $124.83M (32.3%) and Chinese Mainland Public Market at $25.00M (6.5%).
Compared with fiscal 2024, Export grew fastest, up 93.9% to $124.83M, while Chinese Mainland Public Market fell the most, down 50.4% to $25.00M.
Sinovac Biotech began breaking out Chinese Mainland Private Market in fiscal 2023 and Chinese Mainland Public Market in fiscal 2023. Sinovac Biotech stopped reporting Epi ($695.84M in fiscal 2022) and Private Pay ($378.86M in fiscal 2022) as separate revenue lines.
Enterovirus 71 Vaccines was Sinovac Biotech’s largest product and service line in fiscal 2017, bringing in $121.28M of $174.35M (70%).
| Product and Service | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Enterovirus 71 Vaccines | — | — | $35.14M | $121.28M | ||||
| Inactivated Hepatitis Vaccine | $48.45M | $49.42M | — | — | ||||
| Inactivated Hepatitis Vaccines | — | — | $20.60M | $37.85M | ||||
| Inactivated Hepatitis A | — | — | — | — | ||||
| Inactivated Hepatitis Avaccine | — | — | — | — | ||||
| H1 N1 Vaccines | — | — | — | — | ||||
| Influenza Vaccine | $12.13M | $12.67M | — | — | ||||
| Influenza Vaccines | — | — | $9.83M | $13.54M | ||||
| Seasonal Influenza Vaccine | — | — | — | — | ||||
| H5 N1 Vaccines | — | — | — | — | ||||
| Grants For H5N1 2013 Vaccines | — | — | $6.39M | — | ||||
| H5N1 Vaccines | $201.00K | $3.85M | — | — | ||||
| Mumps Vaccines | $2.15M | $1.47M | $477.00K | $1.67M | ||||
| Mumps | — | — | — | — | ||||
| Rabend | — | — | — | — | ||||
| Total | $62.93M | $67.41M | $72.43M | $174.35M |
Sinovac Biotech brought in $174.35M from its four product and service lines in fiscal 2017, the year ended December 31, 2017. Sinovac Biotech regrouped these lines after fiscal 2016, so the total does not compare directly with that year's $72.43M. Enterovirus 71 Vaccines was the largest at $121.28M (69.6%), ahead of Inactivated Hepatitis Vaccines at $37.85M (21.7%) and Influenza Vaccines at $13.54M (7.8%). The remaining line, Mumps Vaccines, brought in $1.67M.
Compared with fiscal 2016, Enterovirus 71 Vaccines grew fastest, up 245.1% to $121.28M. Every line above 2% of revenue grew.
Sinovac Biotech began breaking out Enterovirus 71 Vaccines in fiscal 2016, Inactivated Hepatitis Vaccines in fiscal 2016 and Influenza Vaccines in fiscal 2016. Sinovac Biotech stopped reporting Inactivated Hepatitis Vaccine ($49.42M in fiscal 2015), Influenza Vaccine ($12.67M in fiscal 2015), Grants For H5N1 2013 Vaccines ($6.39M in fiscal 2016) and one other as separate lines.
Sinovac Biotech (SVA) reports its revenue by geography, by contract with customer, sales channel and by product and service. In fiscal 2025, Prc was its largest region, bringing in $261.18M (67.7% of the total), followed by Outside Chinese Mainland at $124.83M (32.3%).
Prc was Sinovac Biotech's largest region in fiscal 2025, bringing in $261.18M, or 67.7% of the $386.01M total across its two regions.
Chinese Mainland Private Market was Sinovac Biotech's largest revenue line in fiscal 2025, bringing in $236.19M, or 61.2% of the $386.01M total across its three revenue lines.
Enterovirus 71 Vaccines was Sinovac Biotech's largest product and service line in fiscal 2017, bringing in $121.28M, or 69.6% of the $174.35M total across its four product and service lines.
Outside Chinese Mainland grew faster than Prc in fiscal 2025, up 93.9% from $64.37M to $124.83M. Prc fell 12.1% to $261.18M.
Every figure comes from Sinovac Biotech's annual financial filings, as reported. Each line keeps the name Sinovac Biotech gives it, and years follow its fiscal calendar.
Sinovac Biotech's revenue by geography goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.